NEW YORK (GenomeWeb) – Nemucore and the Medical Prognosis Institute (MPI) announced today that they have partnered to identify potential responder patients for enrollment in a clinical trial of an undisclosed Nemucore cancer therapeutic.
Under the deal, Nemucore will use MPI's Drug Response Predictor Biomarker platform — which is used to develop tumor-derived gene signatures that may be predictive of how patients respond to certain oncology treatment — to potentially select participants for a planned Phase IIb study of one of its cancer drug candidates.
The drug was undisclosed, but Nemucore said that its most advanced agent is NMI-900, which is expected to enter Phase IIb testing in ovarian cancer later this year.
The companies also said that Nemucore has been given an option to exclusively license and commercialize the biomarker for use as a predictive or companion diagnostics in connection with the drug.
Additional terms of the arrangement were not disclosed.